#1HOLD TAB DOWN TURN Investor Presentation October 2020 2 6mins SENSILE MONCAY GERRESHEIMER#2Disclaimer GERRESHEIMER This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of the Company to differ materially from the estimations expressed or implied herein. The Company does not guarantee that the assumptions underlying such forward-looking statements are free from errors nor does the Company accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast development. ■ No representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, none of the Company or any of its parent or subsidiary undertakings or any of such person's officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document. 13.10.2020 Investor Presentation 2#3Agenda 1 Gerresheimer at a Glance 2 Strategic Direction 3 Q3 Earnings Review 4 Outlook and Executive Summary 5 Market Environment GERRESHEIMER 3#4GERRESHEIMER A leading partner for the global pharma and healthcare industry Gerresheimer at a Glance ■ Pharmaceutical solutions made of glass and plastics Primary packaging products and medical devices for storage, dosage and safe administration of drugs as well as packaging for the cosmetics industry 13.10.2020 Investor Presentation CKSTAR#5Solid Financial Profile Gerresheimer at a Glance Plastics & Devices (P&D) Revenues 2019 EUR 758.3m Adj. EBITDA 2019 EUR 196.4m Contract Design Manufacturing Medical Devices (incl. tooling) Primary Packaging Plastics Prescription Business (Centor, US) Syringes Systems 13.10.2020 Investor Presentation Gerresheimer Group (incl. headquarters) Revenues 2019 EUR 1.40bn Adj. EBITDA 2019 EUR 297m Leverage at 3.2x as of May 31, 2020 Primary Packaging Glass (PPG) Revenues 2019 EUR 631.6m Adj. EBITDA 2019 EUR 122.9m GERRESHEIMER Advanced Technologies (GAT) Revenues 2019 EUR 6.4m Adj. EBITDA 2019 EUR -23.4m Moulded Glass Pharma Moulded Glass Cosmetics (incl. Beverages) Tubular Glass Pharma (Converting) Dedicated to developing and producing intelligent drug delivery systems and value added devices Technology & Platform Operator Own R&D capabilities 5#6Global Footprint and Solid Customer Base Gerresheimer at a Glance GERRESHEIMER Global footprint 37 plants in 15 countries Delivering to 91 countries over 6 continents Over 1,500 customers Supplying all Top 10 Pharma customers Largest customer makes up for ~7% of total revenues 13.10.2020 Investor Presentation Clearly identified revenues streams 6% REVENUE SPLIT BY SECTOR 13% 81% Pharma & Healthcare: 81% Cosmetics: 13% Others: 6% REVENUE SPLIT BY REGIONS 1% 16% Europe (ex. GER): 33% 33% 27% 22% Germany: 22% Americas: 27% Emerging markets1: 16% Other regions: 1% 6#7GERRESHEIMER 15.5bn Products Produced Per Year - Nearly 500 per Second Gerresheimer at a Glance SYRINGES PLASTIC BOTTLES (INCL. CENTOR) PHARMA GLASS COSMETICS BOTTLES .1bn pcs ~ 2.5bn pcs ~ 5.5bn pcs ~ 400m pieces INJECTION VIALS 13.10.2020 ~ 3bn pcs Investor Presentation AMPOULES INHALERS CARTRIDGES 2 2 ~ 2bn pcs ~ 100m pcs ~ 1bn pcs 7#8Agenda 1 Gerresheimer at a Glance 2 Strategic Direction 3 Q3 Earnings Review 4 Outlook and Executive Summary 5 Market Environment GERRESHEIMER 8#9Social and Macroeconomic Trends Fostering Growth Strategic Direction GERRESHEIMER Rise of chronic diseases & aging population Increasing access to healthcare in Emerging Countries Growth in urban population and upper society Increasing trend to self and individual medication New drugs especially in Biosimilars and Biotech Increase importance of sustainability Increasing health costs and stricter regulatory 13.10.2020 Investor Presentation Growing trend to consolidation Faster growth in generic drugs 9#10GERRESHEIMER Clear Definition of Target Markets in Pharma & Healthcare PHARMA VALUE Research Product & Process Production Primary Packaging CHAIN Development Delivery Systems & Assembly Logistics Marketing & Sales Services Suppliers MUST HAVES HARDWARE SERVICES CONSUMABLES Filling machines Blisters Primary packaging glass & plastic, syringes, closures Tools, Gx accessible market Assembly lines for devices Inhalation, injection Infusion, trans- dermal, implants, eye treatment, ear-nose-throat Formulation Product Filling Device (Pre-) analytics design assembly (e.g. sterility) & dev. Logistics 1 Superior product and Technologies 2 Cost leadership 3 Min. #3 for market shares 13.10.2020 Investor Presentation Gx strategic relevant market 10 10#11GERRESHEIMER Gerresheimer is Operating in Large and Attractive Markets Strategic Direction Estimated Market Size 20172 (in € bn) Cosmetics Glass Pharma Glass1 Pharma Plastic Syringes Drug Delivery Devices 2 ~ 1.8 ~ 2.2 ~ 5.8 - 0.9 ~ 4.0 LOW SINGLE DIGIT (in %) Market CAGR '17-'222 MID SINGLE DIGIT The strategic relevant core market for Gerresheimer is today ~ € 15bn 1. Tubular Glass + Moulded Glass Pharma 2. Strategic relevant markets, Gerresheimer estimates 13.10.2020 Investor Presentation 11 1.#12Leading Market Positions in Attractive Niche Markets Strategic Direction GERRESHEIMER DIVISION PLASTICS & DEVICES PRIMARY PACKAGING GLASS PRODUCT Plastic Packaging1 Inhalation (DPI)2 Diabetes Diagnostics³ Pens Syringe Systems MG Pharma (Type I) Ampoules, Vials, Cartridges EUROPE #1 #1 #2 #2 #2 #2 #3 NORTH #1 #1 AMERICA EMERGING #1 MARKETS (South America and India) 1. North America: plastic vials for oral prescription drugs 2. DPI Dry Powder Inhaler (World market) 3. Lancets and lancing devices 13.10.2020 Investor Presentation #1 (South America) #2 #1 #1 #2 #1 (India) (China) 2 12#13GERRESHEIMER We provide Solutions across all Key Product Categories Strategic Direction DIVISION PLASTICS & DEVICES PRIMARY PACKAGING GLASS GAT PRODUCT Plastic Packaging Inhalation (DPI)² Diabetes Diagnostics³ Pens Syringe Systems MG Pharma (Type I) OTC Liquids and Syrups (Type II & III) TG Injectables Sensile Medical Gerresheimer Schott Becton Dickinson1 Nipro¹ Ompi Jabil Circuit (Nypro)1 ✓ ✓ Consort Medical1 West Pharma1 Nemera Berry Plastics1 Facet Ypsomed¹ Desjonquères Rocco Bormioli Insulet ✓ 1. Public company // 2. DPI = Dry Powder Inhaler (World market) // 3. Lancets and lancing devices Source: Company estimates 13.10.2020 Investor Presentation ✓ 13#14Sound Financial Policy Strategic Direction ORGANIC INVESTMENT ■ Capex spend at ~8-10% of sales for growth and maintenance projects Controlled capacity extension ■ Clear payback and IRR criteria DIVIDEND ■Committed to redistributing profit back to shareholders Dividend policy implies payout ratio of 20-30% of adjusted Net Income after minorities 13.10.2020 Investor Presentation GERRESHEIMER Focus on Sustainable and Profitable Growth RATING & LEVERAGE Consider net financial debt to adjusted EBITDA ratio of 2.5 as appropriate for Gerresheimer Temporary variation tolerated in case of relevant M&A Committed to investment grade rating in the long term M&A Stringent and selective approach to acquisitions Strategic fit, management profile and financial track record as key initial considerations Clear financial guidelines 14 14#15Agenda 1 Gerresheimer at a Glance 2 Strategic Direction 3 Q3 Earnings Review 4 Outlook and Executive Summary 5 Market Environment GERRESHEIMER 15#16On Track: We Deliver on our Promises Q3 Earnings Review: Key Take-Aways Q3 2020 GERRESHEIMER Third quarter as expected: □ accomplishing growth despite Covid-19 Backend-loaded fiscal year: very strong Q4 ahead ■ Financial highlights in Q3: ☐ Revenues of EUR 349m ☐ Organically +2.1% in core business1 Adjusted EBITDA of EUR 75m, adj. EBITDA margin 21.5% ■ Strong free cash flow in Q3: EUR 38m representing strong earnings quality ■ Guidance confirmed 1. Pushing forward the implementation of our growth strategy The core business consists of the Plastics & Devices and the Primary Packaging Glass Divisions; for adjusted EBITDA purposes also including head office/consolidation. 13.10.2020 Investor Presentation 16 16#17GERRESHEIMER Gx® Biological Solutions Pushed Forward Advanced Solutions for Biotechs Highly dynamic market environment The industry is witnessing a paradigm shift from small molecules towards biologicals and new modalities Market for small molecules will remain strong The fast-growing biologicals sector will generate significant growth opportunities for Gerresheimer Gx® Biological Solutions serving customers' needs: Gx® Biological Solutions: ° Dedicated unit with technical and development expertise Best possible packaging configuration Lab services, regulatory and qualification support now available in Europe and US Full-service provider for small, mid and large biotech companies The right product solutions Serving biotech customers with the whole Gerresheimer portfolio Main contributors for growth: RTF vials Elite vials RTF syringes 13.10.2020 Investor Presentation 17 15#18GERRESHEIMER Further Capacity Increase for Vials and Syringes Fully Ongoing Gx as Reliable Partner for Pharma and Healthcare Growing injectables market as global mega trend ■ Vaccination as global mega trend Covid-19 is expected to boost the market Therapeutics are switching from chemical to biological Recurrent vaccination increases demand for syringes Clearly standing by our responsibility Assumption for Covid-19 vials proving conservative Global demand of 2-3bn units for Covid-19 vaccination in 2021/2022 Customers demanding single and multi-dose vials At least 800m units foreseen to be delivered over the next two years Capacity increase to serve global demand Investments brought forward: Vials: New machines being installed, including new RTF vials machine in Buende Syringes: RTF 5 line ramping up, RTF 6 line to start production mid-2021 13.10.2020 Investor Presentation 18 18#19GERRESHEIMER Accelerating Change - Transforming Gerresheimer in Full Swing Update to follow at Capital Markets Day Virtual Capital Markets Day Time Section (CET) ■ December 8, 2020 - 2:00pm Welcome fully virtual and interactive 2:05pm Update on growth strategy 2:50pm Our Growth Strategy - Leading in Health and Well-Being Delivery Solutions Financial Foundation for our Growth Strategy and investment plans. 3:20pm Driving Innovation & Digitalization Digital meeting with 3:40pm Q&A Session I experts for technology, excellence, innovation 4:00pm Break Interactive Discussion in Expert Sessions 4:15pm Focus on ambitious ESG - Three Live Streams - strategy 5:15pm Q&A Session II 5:30pm Wrap-Up 5:45pm Closing CMD 13.10.2020 Investor Presentation 19 19#20Q3 2020 - Solid Basis Anticipating Very Strong Q4 P&L Overview GERRESHEIMER (EUR m) Revenues Adj. EBITDA Q3 2020 Q3 2019 YoY 349.2 358.6 0.4% 1) 75.0 72.2 1.8% 1) Analysis Organic growth of +2.1% in core business including temporary Covid-19 one-time hit in cosmetics of a mid-single digit Euro amount Profitability increase due to good core business performance; excellent organic growth of +8.6% in core business One-off effects 3.1 -1.1 EBITDA 78.1 71.1 Depreciation, amortization & impairment -34.3 -37.3 Due to lower fair value amortization Net finance expense -5.5 -7.0 Income taxes -12.7 -7.8 Net income 25.6 19.0 Adjustment 5.1 11.7 Adj. net income 30.7 30.7 Adj. EPS 0.97 0.96 1. Organically, adjusted for exchange rate effects and acquisitions and divestments as well as regarding adj. EBITDA excluding the effects from the first-time application of IFRS 16. 13.10.2020 Investor Presentation 20 20#21GERRESHEIMER Robust Core Business: Organic Growth Despite Covid-19 Q3 2020 Divisions EUR m P&D PPG GAT 193.7 193.8 Organic growth +4.3% 52.1 Organic growth +13.5% 45.7 Q3 2020 Q3 2019 Revenues Q3 2019 Q3 2020 Adj. EBITDA Organic growth -0.5% 31.9 Organic growth +3.5% 159.2 30.1 155.8 Q3 2019 Q3 2020 Q3 2019 Q3 2020 Revenues Adj. EBITDA 6.3 1.8 Q3 2019 Q3 2020 0.6 -2.7 Q3 2019 Q3 2020 Revenues 13.10.2020 Investor Presentation Adj. EBITDA Strong growth in PPP and syringes, short-term phasing effects in MDS Margin improvement to 26.9% on the back of organic adj. EBITDA growth of 13.5% Negative Covid-19 one-time hit of around EUR 6m in the cosmetics business - Organic revenue growth of +5% disregarding the cosmetic business Margin improvement to 20.5% on the back of organic adj. EBITDA growth of 3.5% - Advanced Technologies as innovation driver and long-term investment case Change of revenue model: From contract developer for PharmaCo to a revenue sharing partner of PharmaCo 21 21#22Outperformance in Free Cash Flow Cash Flow in Q3 2020 GERRESHEIMER (EUR m) Adjusted EBITDA Q3 2020 Q3 2019 Change Analysis 75.0 72.2 2.8 Driven by good core business Change in net working capital 4.7 -12.4 17.1 Focus on operational Working Capital performance Net capex -28.8 -43.6 14.8 Supported by sale of Kuessnacht site Net interest paid -2.3 -2.4 0.1 Net taxes paid -8.2 -8.2 Pension benefits paid -2.4 -3.2 0.8 Other -0.3 -5.2 4.9 Free Cash Flow before M&A 37.7 -2.8 40.5 13.10.2020 Investor Presentation 22 22#23GERRESHEIMER Leverage Stable - Promissory Note Agreement Signed - End of Q3 2020: Financial Status NET FINANCIAL DEBT AND ADJ. EBITDA LEVERAGE NET FINANCIAL DEBT ACCORDING TO CREDIT AGREEMENT IN FORCE 1) 976.0 980.7 In EUR m May 2020 Aug 2020 Revolving credit facility 360.2 365.5 3.2 -3.2 Promissory loans (2017) 250.0 250.0 Promissory loans (2015) 425.0 425.0 Local borrowings 33.1 33.6 May 31 2020 Aug 31 2020 Installment purchase liabilities 1.7 1.7 Net financial debt according to the credit agreement in force¹) Adj. EBITDA leverage (x) Cash and cash equivalents (94.0) (95.1) Net financial debt according to credit agreement in force 1) 976.0 980.7 EXPIRY DATE MAIN FACILITIES 189.5 305.5 550.0 109.0 25.5 45.5 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 FY 2027 STATUS OF CURRENT PROMISSORY LOAN TRANSACTION Successful refinancing the promissory loans maturing in November 2020 EUR 325m promissory loan agreement signed Conditions towards former promissory loan improved Highly oversubscribed: sustained confidence in Gerresheimer's business model Closing expected for early November 2020 ■RCF Promissory loans 1. Without base liabilities 13.10.2020 Investor Presentation 23 23#24Agenda 1 Gerresheimer at a Glance 2 Strategic Direction 3 Q3 Earnings Review 4 Outlook and Executive Summary 5 Market Environment GERRESHEIMER 24 24#25Very Strong Quarter Ahead Outlook Q4 2020 P&D Mid to high-single digit growth PPG GAT 13.10.2020 Investor Presentation Support of phasing effects from Q3 High-single digit to double digit growth ■First delivery of Covid-19 vials Innovation materializing: first sales in Gx® Elite Glass First recovery in cosmetics business Exploration of further technologies, opportunities and new projects SQ Innovation project on track GERRESHEIMER 25#26Guidance Confirmed Revenue Growth Adjusted EBITDA Capex (% of revenues) 13.10.2020 Investor Presentation FY 2020 Mid-single digit growth ~21%1 P - 12% GERRESHEIMER Mid-term Mid-single digit growth At Group level (FXN) P 23% 8-10% 26#27Focus on Growth Q3 2020: Core business on track Very strong quarter ahead GERRESHEIMER For our long-term profitable growth journey we are securing new orders, additional capacities and leveraging market trends 13.10.2020 Investor Presentation 27 27#28Executive Summary 13.10.2020 Investor Presentation GERRESHEIMER ◉ Strong customers focus from the non-cyclical pharma and healthcare market with long-term growth prospects supported by megatrends Market-leading positions in attractive niche markets Robust business supporting stable operating margins through the cycle Good track record of generating solid free cash flow with high forecast accuracy Solid financial profile and comfortable headroom Guidance FY 2020 confirmed striving for sustainable profitable growth 28 20#29Agenda 1 Gerresheimer at a Glance 2 Strategic Direction 3 Q3 Earnings Review 4 Outlook and Executive Summary 5 Market Environment GERRESHEIMER 29 29#30Current customer overview 1 Teva L'Oreal Beiersdorf Mylan Astra Bayer ABOUT 7% generated with our Top 1 customer P&G Sanofi Coty Roche 35% of revenues generated with our Top 10 Pharma & Generics customers in 2018 J&J Pfizer 48% of revenues generated with our Top 20 Pharma & Generics customers in 2018 Novo Nordisk Fresenius Boehringer Ingelheim Merck GSK Avon Novartis 1. Customers names have been inputted randomly and clock-wise presentation does not correspond to revenues ranking 13.10.2020 Investor Presentation GERRESHEIMER 30 30#31as well as in Cosmetics GERRESHEIMER COSMETIC VALUE Product & Research CHAIN Process Development Production Primary Packaging & Decoration Delivery Systems & Assembly Logistics Marketing & Sales Services Suppliers MUST HAVES HARDWARE SERVICES CONSUMABLES Filling machines Plastic Bottles Moulded Glass Packaging Samples & Decoration Gx accessible market Formulation Product analytics Filling Components (Pumps & Caps) Innovative bottle design & development Component pre-assembly & sealing 1 Superior product and Technologies 2 Cost leadership 3 Min. #3 for market shares 13.10.2020 Investor Presentation relevant market Gx strategic 31 31#32Underlying market growth 1. IQVIA (former Quintiles IMS) January 2020. 2. Generic units are included in Medicine units. 13.10.2020 Investor Presentation GERRESHEIMER Expected development of Pharma market volumes 1 CAGR '20-24 (in %) Medicine Generic standard standard units units² Global 1.5% 1.9% Developed markets -0.3% 0.1% Pharmerging markets 2.6% 3.1% ROW 0.6% 0.9% Global volume growth '19 1.4% 2.6% 32 32#33Financial Calendar 2020 H FINANCIAL CALENDAR Capital Markets Day December 8, 2020 February 18, 2021 Annual Report 2020 April 8, 2021 June 9, 2021 July 13, 2021 October 12, 2021 Publication 1st Quarter 2021 Annual General Meeting 2021 Interim Report 2nd Quarter 2021 Publication 3rd Quarter 2021 13.10.2020 Investor Presentation 2т бл SENSILE TURN GERRESHEIMER 33 33#34Overview of Abbreviations and Definitions GERRESHEIMER ABBREVIATIONS AND DEFINITIONS Adj. EBITDA Adjusted EPS Adjusted net income CAGR Net income before income taxes, net finance expense, amortization of fair value adjustments, depreciation and amortization, impairment losses, restructuring expenses and one-off income and expenses Adjusted earnings per share after non-controlling interests, divided by 31.4m shares - Net income before non-cash amortization of fair value adjustments, non-recurring effects of restructuring expenses, portfolio adjustments, the balance of one-off income and expenses - including significant non-cash expenses and the related tax effects Compound Annual Growth Rate Investments in tangible and intangible assets Earnings before interest and taxes Capex EBIT EBITA Earnings before interest, taxes and amortization EBITDA FXN Gx ROCE Gx RONOA Earnings before interest, taxes, depreciation and amortization "Foreign currency neutral" - based on budgeted FX-rates Adjusted EBITA divided by capital employed (total assets minus investments, investments accounted for using the equity method and other loans, minus cash and cash equivalents, minus pensions (without pension provisions), deferred tax liabilities, and income tax liabilities, minus prepayments received, trade payables, and other non-interest bearing liabilities) The ratio of adjusted EBITA to average net operating assets, comprising the sum of property, plant and equipment and net working capital Adj. EBITDA Leverage The relation of net financial debt to adjusted EBITDA of the last twelve months, according to the credit facility agreement currently in place Net financial debt Short and long term debt minus cash and cash equivalents Net finance expense Net working capial (NWC) Op. CF margin Operating cash flow P/E Ratio RCF yoy Interest income and expenses related to the net financial debt of the Gerresheimer Group. It also includes net interest expenses for pension provisions together with exchange rate effects from financing activities and from related derivative hedges. Inventories plus trade receivables minus trade payables plus/minus prepayments Adjusted EBITDA plus/minus the change in net working capital, minus capex and in relation to revenues Adjusted EBITDA plus/minus change in net working capital, minus capex Company's share price divided by the adj. EPS Revolving credit facility year-on-year 13.10.2020 Investor Presentation 34 44#35HOLD TAB DOWN TURN 2 6mins SENSILE MONCAY GERRESHEIMER Our Vision Gerresheimer will become the leading global partner for enabling solutions that improve health and well-being. Our success is driven by the passion of our people.